Clinical and metabolic characteristics of patients with latent autoimmune diabetes in adults (LADA): Absence of rapid beta-cell loss in patients with tight metabolic control

Diabetes and Metabolism

Volumn 36, Issue 1, 2010, Pages 64-70

  Chaillous, L ^a,b   Bouhanick, B ^c   Kerlan, V ^d   Mathieu, E ^e   Lecomte, P ^f   Ducluzeau, P H ^c   Delamaire, M ^g   Sonnet, E ^d   Maugendre, D ^h   Marechaud R ⁱ   Rohmer, V ^c   Sai P ^b   Charbonnel, B ^a,b  

^a L INSTITUT DU THORAX   (France)

^b UNIVERSITÉ DE NANTES   (France)

^c ANGERS UNIVERSITY HOSPITAL   (France)

^d SERVICE DE RHUMATOLOGIE   (France)

^e Universite d'Angers   (France)

^f CHU BRETONNEAU   (France)

^g Ctr Regionale de Transfus Sang   (France)

^h SERVICE DE RHUMATOLOGIE   (France)

ⁱ Cité hospitalière La Milétrie ^*  (France)

Author keywords

C peptide; Insulin secretion; LADA

Indexed keywords

C PEPTIDE; GLUCOSE; GLUTAMATE DECARBOXYLASE ANTIBODY; HEMOGLOBIN A1C; INSULIN; ORAL ANTIDIABETIC AGENT; PANCREAS ISLET CELL ANTIBODY;

ADULT; AGED; ARTICLE; AUTOIMMUNE DISEASE; CELL FUNCTION; CELL LOSS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIABETIC PATIENT; DISEASE COURSE; FEMALE; FOLLOW UP; GLYCEMIC CONTROL; HUMAN; INSULIN TREATMENT; LATENT AUTOIMMUNE DIABETES IN ADULT; LATENT AUTOIMMUNE DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; METABOLIC REGULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PROSPECTIVE STUDY;

ADULT; AGE OF ONSET; AGED; BIOLOGICAL MARKERS; BLOOD GLUCOSE; BODY MASS INDEX; C-PEPTIDE; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 1; DISEASE PROGRESSION; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN-SECRETING CELLS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 76749106089     PISSN: 12623636     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabet.2009.07.004     Document Type: Article

References (30)

1. Irvine W.J., Gray R.S., Mccallum C.J., and Duncan L.J.P. Clinical and pathogenic significance of pancreatic islet-cell antibodies in diabetics treated with oral hypoglycaemic agents. Lancet 309 (1977) 1025-1027
2. Groop I.C., Bottazzo G.F., and Doniach D. Islet cell antibodies identify latent type 1 diabetes in patients aged 35-75 years at diagnosis. Diabetes 35 (1986) 237-241
3. Tuomi T., Groop L.C., Zimmet P.Z., Rowley M.J., Knowles W., and Mackay I.R. Antibodies to glutamic acid decarboxylase reveal latent autoimmune diabetes mellitus in adults with a non-insulin-dependent onset of disease. Diabetes 42 (1993) 359-362
4. Kobayashi T., Tamemoto K., Nakanishi K., Kato N., Okubo M., Kajio H., et al. Immunogenetic and clinical characterization of slowly progressive IDDM. Diabetes Care 16 (1993) 7080-7088
5. Leslie R.D.G., Williams R., and Pozzilli P. Type 1 diabetes and latent autoimmune diabetes in adults: one end of the rainbow. J Clin Endocrinol Metab 91 (2006) 1654-1659
6. Turner R., Stratton I., Horton V., Manley S., Zimmet P., Mackay I.R., et al. UKPDS 25 : autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes. Lancet 350 (1997) 1288-1293
7. Landin-Olsson M., Nilsson K.O., Lernmark A., and Sundkvist G. Islet cell antibodies and fasting C-peptide predict insulin requirement at diagnosis of diabetes mellitus. Diabetologia 33 (1990) 561-568
8. Gottsäter A., Landin-Olsson M., Fernlund P., Lernmark A., and Sundkvist G. Beta-cell function in relation to islet cell antibodies during the first 3 yr after clinical diagnosis of diabetes in type II diabetic patients. Diabetes Care 16 (1993) 902-910
9. Borg H., Gottsäter A., Fernlund P., and Sundkvist G. A 12-year prospective study of the relationship between islet antibodies and ß-cell function at and after the diagnosis in patients with adult-onset diabetes. Diabetes 51 (2002) 1754-1762
10. Zimmet P.Z., Tuomi T., Mackay I.R., Rowley M.J., Knowles W., Cohen M., et al. Latent autoimmune diabetes mellitus in adults (LADA): the role of antibodies to glutamic acid decarboxylase in diagnosis and prediction of insulin independency. Diabet Med 11 (1994) 299-303
11. Gottsäter A., Landin-Olsson M., Lernmark A., Fernlund P., Sundkvist G., and Hagopian W.A. Glutamate decarboxylase antibody levels predict rate of ß -cell decline in adult-onset diabetes. Diabetes Res Clin Pract 27 (1995) 133-140
12. Tuomi T., Carlsson A., Li H., Isomaa B., Miettinen A., Nilsson A., et al. Clinical and genetic characteristics of type 2 diabetes with and without GAD antibodies. Diabetes 48 (1999) 150-157
13. Carlsson A., Sundkvist G., Groop L., and Tuomi T. Insulin and glucagon secretion in patients with slowly progressing autoimmune diabetes (LADA). J Clin Endocrinol Metab 85 (2000) 76-80
14. Davis T.M., Wright A.D., Mehta Z.M., Cull C.A., Stratton I.M., Bottazzo G.F., et al. Islet autoantibodies in clinically diagnosed type 2 diabetes: prevalence and relationship with metabolic control (UKPDS 70). Diabetologia 48 (2005) 695-702
15. Kobayashi T., Nakanishi K., Murase T., and Kosaka K. Small doses of subcutaneous insulin as a strategy for preventing slowly progressive beta-cell failure in islet cell antibody-positive patients with clinical features of NIDDM. Diabetes 45 (1996) 622-626
16. Maruyama T., Tanaka S., Shimada A., Funae O., Kasuga A., Kanatsuka A., et al. Insulin intervention in slowly progressive insulin-dependent (type 1) diabetes mellitus. J Clin Endocrinol Metab 93 (2008) 2115-2121
17. Brophy S., Brunt H., Davies H., Mannan S., Williams R., et al. Interventions for latent autoimmune diabetes (LADA) in adults. Cochrane Database Syst Rev 18 (2007) CD006165
18. Chaillous L., Delamaire M., Elmansour A., Maugendre D., Rohmer V., Joseph M.G., et al. Combined analysis of islet cell antibodies which cross-react with mouse pancreas, antibodies to the M(r) 64,000 islet protein, and antibodies to glutamate decarboxylase in subjects at risk for IDDM. Diabetologia 37 (1994) 491-499
19. Chaillous L., Lefèvre H., Thivolet C., Boitard C., Lahlou N., Atlan-Gepner C., et al. Oral insulin administration and residual beta-cell function in recent-onset type 1 diabetes: a multicentre randomised controlled trial. Diabète Insuline Orale Group. Lancet 356 (2002) 545-549
20. Stenström G., Gottsäter A., Bakhtadze E., Berger B., and Sundkvist G. Latent autoimmune diabetes in adults: definition, prevalence, beta-cell function and treatment. Diabetes 54 (2005) S68-72
21. Gotfredsen C.F., Buschard K., and Frandsen E.K. Reduction of diabetes incidence of BB Wistar rats by early prophylactic insulin treatment of diabetes-prone animals. Diabetologia 28 (1985) 933-935
22. Atkinson M.A., Maclaren N.K., and Luchetta R. Insulitis in diabetes in NOD mice reduced by prophylactic insulin therapy. Diabetes 39 (1990) 933-937
23. Keller R.J., Eisenbarth G.S., and Jackson R.A. Insulin prophylaxis in individuals at high risk of type 1 diabetes. Lancet 341 (1993) 927-928
24. Diabetes Prevention Trial Type 1 Diabetes Study Group. Effects of insulin in relatives of patients with type 1 diabetes mellitus. N Engl J Med 346 (2002) 1685-1691
25. Desai M., and Clark A. Autoimmune diabetes in adults: lessons from the UKPDS. Diabet Med 25 suppl 2 (2008) 30-34
26. Alvarsson M., Sundkvist G., Lager I., Henricsson M., Berntorp K., Fernqvist-Forbes E., et al. Beneficial effects of insulin versus sulphonylurea on insulin secretion and metabolic control in recently diagnosed type 2 diabetic patients. Diabetes Care 26 (2003) 2231-2237
27. Agardh C.D., Cilio C.M., Lethagen A., Lynch K., Leslie R.D., Palmér M., et al. Clinical evidence for the safety of GAD65 immunomodulation in adult-onset autoimmune diabetes. J Diabetes Complications 19 (2005) 238-246
28. Pozzilli P., and Guglielmi C. Immunomodulation for the prevention of SPIDDM and LADA. Ann N Y Acad Sci 1079 (2006) 90-98
29. Brophy S., Davies H., Bain S., Stephens J.W., Cheung W.Y., Richards K., et al. Randomized, controlled, parallel-group prospective study to investigate the clinical effectiveness of early insulin treatment in patients with latent autoimmune diabetes in adults. BMC Endocr Disord 8 (2008) 8
30. Detournay B., Cros S., Charbonnel B., Grimaldi A., Liard F., Cogneau J., et al. Managing type 2 diabetes in France: the ECODIA survey. Diabetes Metab 26 (2000) 363-369